This Phase 3 randomized, open-label, multicenter, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir-resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as a first dose to rapidly reach steady-state plasma concentration) or foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours.

Currently, 153 people ages 16 and older are participating in this clinical trial.